ARYA Sciences Acquisition Corp III
Status: Deal Closed
U=S
IPO Proceeds, $M | $149.50M |
---|---|
IPO Date | Aug 7, 2020 |
CEO | Adam Stone |
Left Lead | Jefferies |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 months |
IPO Sector |
Healthcare
Life sciences and medical technologies in North America and Europe |
IPO Geography | Global |
Target Company | Nautilus Biotechnology |
Deal Announced | Feb 8, 2021 |
Deal Size, $M | $905.37M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Jun 8, 2021 |
Amendment Vote | TBD |
Closing Date | Jun 9, 2021 |
Formerly ARYA
NAUT
Price | $2.04 |
---|---|
Last closing price | $2.08 |
H/L, 52-week | $1.50 / $4.65 |
Volume, today | 96,869 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on ARYA Sciences Acquisition Corp III:
- Structure and cap table
- 7 directors & officers
- 17 filings and events
- 2 underwriters
- 5 deal advisors
- 3 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Joseph Edelman | 64 | Chairman |
Adam Stone | 40 | CEO and Director |
Michael Altman | 38 | CFO and Director |
Konstantin Poukalov | 36 | Chief Business Officer |
Todd Wider | 55 | Director |
Bradley L. Campbell | 45 | Director |
Saqib Islam | 51 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Jefferies | Joint BR | 6,500,000 | units |
Goldman Sachs | Joint BR | 6,500,000 | |
13,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.